Event | 34th Annual Roth Conference |
Date | March 15, 2022 |
Time | 2:30 PM Pacific Time (5:30 PM Eastern Time) |
Format | Fireside Chat |
Link | https://wsw.com/webcast/roth43/nvct/1845484 |
About Nuvectis Pharma
Nuvectis Pharma, Inc. is a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. The Company's pipeline includes NXP800, a clinical-stage HSF1-pathway inhibitor, and NXP900, a SRC/YES1 kinase inhibitor in IND-enabling pre-clinical testing.
For more information, please visit www.nuvectis.com.
Nuvectis Pharma Contact:
Ron Bentsur
Chairman, Chief Executive Officer and President
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Relations Contact:
LifeSci Advisors on behalf of Nuvectis Pharma, Inc.
Eric Goldstein
Tel: 646-791-9729
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$6.15 |
Daily Change: | -0.38 -5.82 |
Daily Volume: | 109,582 |
Market Cap: | US$112.980M |
April 08, 2024 December 18, 2023 |
DevvStream provides upfront capital for sustainability projects in exchange for carbon credit rights. Through these rights, the company generates and manages carbon credits by utilizing the most technologically advanced...
CLICK TO LEARN MORESienna Resources is at the forefront of the battery metals revolution. The company is one of the largest landholders in the prolific Clayton Valley district, which is the only lithium producing region in the United States and located just miles...
CLICK TO LEARN MORECOPYRIGHT ©2022 GREEN STOCK NEWS